Imperatorin Inhibits Proliferation, Migration, and Inflammation via Blocking the NF-κB and MAPK Pathways in Rheumatoid Fibroblast-like Synoviocytes

Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the e...

Full description

Saved in:
Bibliographic Details
Published in:ACS omega Vol. 7; no. 34; pp. 29868 - 29876
Main Authors: Lin, Wei, Chen, Gang, Mao, Yuhang, Ma, Xuemei, Zhou, Junnan, Yu, Xiaolu, Wang, Chaoliang, Liu, Mei
Format: Journal Article
Language:English
Published: American Chemical Society 30-08-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment.
AbstractList Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment.
Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for natural compounds that may suppress the activation of FLSs has become a complementary approach for RA treatment. Here, we investigated the effects and mechanisms of imperatorin (IPT) on proliferation, migration, and inflammation in primary cultured arthritic FLSs. We found that IPT significantly suppressed TNFα-induced proliferation and migration of arthritic FLSs, but showed little effect on survival and apoptosis. In addition, IPT treatment significantly reduced the TNFα-induced expression of pro-inflammatory cytokines (IL-1β, TNFα, IL-6, and IL-8) in arthritic FLSs. Further mechanism studies suggested that IPT inhibited the activations of p38 and extracellular signal-regulated kinase (ERK). Also, IPT blocked the nuclear factor of κB (NF-κB) activation by suppressing the phosphorylation and degradation of IκBα, thereby preventing the translocation of p65. Collectively, our results demonstrated that IPT could inhibit the over-activated phenotypes of arthritic FLSs via the mitogen-activated protein kinase (MAPK) (p38 and ERK) and NF-κB pathways leading to the down-regulation of pro-inflammatory cytokines, which might be beneficial to the anti-proliferative and anti-migratory activities of FLS cells. These findings suggest that IPT has the potential to be developed as a novel agent for RA treatment.
Author Zhou, Junnan
Yu, Xiaolu
Chen, Gang
Mao, Yuhang
Wang, Chaoliang
Ma, Xuemei
Lin, Wei
Liu, Mei
AuthorAffiliation Spine and Joint Surgery
People’s Hospital Affiliated to Shandong First Medical University
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
AuthorAffiliation_xml – name: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– name: People’s Hospital Affiliated to Shandong First Medical University
– name: Spine and Joint Surgery
Author_xml – sequence: 1
  givenname: Wei
  surname: Lin
  fullname: Lin, Wei
  organization: People’s Hospital Affiliated to Shandong First Medical University
– sequence: 2
  givenname: Gang
  surname: Chen
  fullname: Chen, Gang
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– sequence: 3
  givenname: Yuhang
  surname: Mao
  fullname: Mao, Yuhang
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– sequence: 4
  givenname: Xuemei
  surname: Ma
  fullname: Ma, Xuemei
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– sequence: 5
  givenname: Junnan
  surname: Zhou
  fullname: Zhou, Junnan
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– sequence: 6
  givenname: Xiaolu
  surname: Yu
  fullname: Yu, Xiaolu
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
– sequence: 7
  givenname: Chaoliang
  surname: Wang
  fullname: Wang, Chaoliang
  email: lwwcl2003@163.com
  organization: People’s Hospital Affiliated to Shandong First Medical University
– sequence: 8
  givenname: Mei
  orcidid: 0000-0002-4960-0096
  surname: Liu
  fullname: Liu, Mei
  email: meiliunj@163.com
  organization: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences
BookMark eNp1kc9O3DAQxq0KVCjl3qOPPRCwncRJLpUAddsV0K7652w5znhjcOzFTrba9-jT9CH6TBh2qdpDTx7N_L5vNP5eoT3nHSD0hpJTShg9kyr6AZbylCnCKs5foENWVCSjeZHv_VUfoOMYbwkhlNesZvwlOsg54ZQ39BD9nA8rCHL0wTg8d71pzRjxInhr9GPfeHeCb8zyuZSuS5i2chieOnhtJL6wXt0Zt8RjD_jTLPv96-IJvDlfXOGFHPsfchNxWvClhynpvOnwzLTBt1bGMbPmDvDXjfNr49VmhPga7WtpIxzv3iP0ffb-2-XH7Przh_nl-XUmWVnyDChtdFEVLS-5IpyUALRtOqVbWQGvNWk6ynQ6FDSjDOqiprIkoFhZ6VrVLD9C77a-q6kdoFPgxiCtWAUzyLARXhrx78SZXiz9WjRFXlQVSQZvdwbB308QRzGYqMBa6cBPUbCKNA3NaV4llGxRFXyMAfSfNZSIxzzFc55il2eSnGwlaSJu_RRc-oz_4w9k4KgD
CitedBy_id crossref_primary_10_1007_s12018_024_09290_7
crossref_primary_10_1007_s10787_023_01369_9
crossref_primary_10_1016_j_ejphar_2023_176250
crossref_primary_10_3389_fphar_2023_1230293
crossref_primary_10_3390_ijms242115793
Cites_doi 10.1016/j.jbspin.2011.03.018
10.1021/acs.analchem.5b04064
10.3390/biom9120795
10.1186/s12979-019-0169-4
10.1186/s13075-019-1935-6
10.3892/etm.2016.3172
10.1016/j.toxlet.2011.11.030
10.3892/or.2016.4586
10.1093/rheumatology/kem298
10.1007/s10456-015-9477-2
10.1021/jf204297e
10.1038/s41413-018-0016-9
10.1021/acs.analchem.7b03114
10.1016/j.yrtph.2014.05.025
10.1186/ar3324
10.1093/rheumatology/kel065
10.1016/j.snb.2020.128486
10.1016/j.bcp.2020.114401
10.1007/s00044-014-1233-4
10.1073/pnas.1814777116
10.3109/08830185.2014.938325
10.1016/j.intimp.2019.03.008
10.2147/BTT.S35475
10.1101/cshperspect.a001651
10.1080/21655979.2021.2012949
10.1016/j.autrev.2020.102741
10.1111/j.0105-2896.2009.00859.x
10.1002/art.40504
10.1039/c7fo01748k
10.3892/mmr.2017.7706
10.1038/s41413-019-0047-x
10.1007/s10753-020-01371-1
10.1006/cimm.1994.1223
10.3390/ijms19051514
10.1016/j.intimp.2021.107392
10.1038/nprot.2007.173
10.1002/jcp.26754
10.1186/ar1038
10.1038/nbt1328
10.1186/s12967-021-03169-7
10.1016/j.cmet.2010.12.008
10.1186/1471-2474-12-153
10.3389/fphar.2021.670707
10.4049/jimmunol.1600600
10.1038/s41423-019-0201-9
10.1155/2020/2138186
10.1002/pds.3221
10.1155/2021/6617312
10.1016/j.toxicon.2019.06.007
10.3390/ijms23105813
ContentType Journal Article
Copyright 2022 The Authors. Published by American Chemical Society
2022 The Authors. Published by American Chemical Society 2022 The Authors
Copyright_xml – notice: 2022 The Authors. Published by American Chemical Society
– notice: 2022 The Authors. Published by American Chemical Society 2022 The Authors
DBID N~.
AAYXX
CITATION
7X8
5PM
DOI 10.1021/acsomega.2c02766
DatabaseName American Chemical Society Journals
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 2470-1343
EndPage 29876
ExternalDocumentID 10_1021_acsomega_2c02766
c301267890
GrantInformation_xml – fundername: ;
  grantid: NA
GroupedDBID 53G
ABFRP
ABUCX
ACS
ADBBV
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
EBS
GROUPED_DOAJ
HYE
N~.
OK1
RPM
VF5
AAFWJ
AAHBH
AAYXX
AFPKN
CITATION
M~E
7X8
5PM
ID FETCH-LOGICAL-a2556-e119f474b656c0605ee1b9dcfba7e68f09d12f616ef212e8481a50ec257f8c823
IEDL.DBID RPM
ISSN 2470-1343
IngestDate Tue Sep 17 21:34:14 EDT 2024
Fri Aug 16 23:51:50 EDT 2024
Fri Aug 23 01:21:48 EDT 2024
Thu Sep 01 03:10:33 EDT 2022
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 34
Language English
License Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a2556-e119f474b656c0605ee1b9dcfba7e68f09d12f616ef212e8481a50ec257f8c823
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4960-0096
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434770/
PMID 36061691
PQID 2709913137
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9434770
proquest_miscellaneous_2709913137
crossref_primary_10_1021_acsomega_2c02766
acs_journals_10_1021_acsomega_2c02766
PublicationCentury 2000
PublicationDate 20220830
PublicationDateYYYYMMDD 2022-08-30
PublicationDate_xml – month: 08
  year: 2022
  text: 20220830
  day: 30
PublicationDecade 2020
PublicationTitle ACS omega
PublicationTitleAlternate ACS Omega
PublicationYear 2022
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref52/cit52
ref23/cit23
ref8/cit8
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref17/cit17
ref10/cit10
ref35/cit35
ref53/cit53
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref24/cit24
ref38/cit38
Zhai K. (ref19/cit19) 2014; 76
ref50/cit50
ref6/cit6
ref36/cit36
ref18/cit18
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref40/cit40
Li-xin W. (ref16/cit16) 2018
ref26/cit26
ref12/cit12
ref15/cit15
ref41/cit41
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
References_xml – ident: ref44/cit44
  doi: 10.1016/j.jbspin.2011.03.018
– ident: ref11/cit11
  doi: 10.1021/acs.analchem.5b04064
– ident: ref5/cit5
  doi: 10.3390/biom9120795
– ident: ref30/cit30
  doi: 10.1186/s12979-019-0169-4
– volume: 76
  start-page: 445
  year: 2014
  ident: ref19/cit19
  publication-title: Indian J. Pharm. Sci.
  contributor:
    fullname: Zhai K.
– ident: ref4/cit4
  doi: 10.1186/s13075-019-1935-6
– ident: ref18/cit18
  doi: 10.3892/etm.2016.3172
– ident: ref50/cit50
  doi: 10.1016/j.toxlet.2011.11.030
– ident: ref15/cit15
  doi: 10.3892/or.2016.4586
– ident: ref47/cit47
  doi: 10.1093/rheumatology/kem298
– ident: ref31/cit31
  doi: 10.1007/s10456-015-9477-2
– ident: ref17/cit17
  doi: 10.1021/jf204297e
– ident: ref39/cit39
  doi: 10.1038/s41413-018-0016-9
– ident: ref10/cit10
  doi: 10.1021/acs.analchem.7b03114
– ident: ref51/cit51
  doi: 10.1016/j.yrtph.2014.05.025
– ident: ref27/cit27
  doi: 10.1186/ar3324
– ident: ref28/cit28
  doi: 10.1093/rheumatology/kel065
– ident: ref12/cit12
  doi: 10.1016/j.snb.2020.128486
– ident: ref35/cit35
  doi: 10.1016/j.bcp.2020.114401
– ident: ref36/cit36
  doi: 10.1021/jf204297e
– start-page: 20
  year: 2018
  ident: ref16/cit16
  publication-title: Chin. J. Exp. Tradit. Med. Formulae
  contributor:
    fullname: Li-xin W.
– ident: ref52/cit52
  doi: 10.1007/s00044-014-1233-4
– ident: ref13/cit13
  doi: 10.1073/pnas.1814777116
– ident: ref25/cit25
  doi: 10.3109/08830185.2014.938325
– ident: ref32/cit32
  doi: 10.1016/j.intimp.2019.03.008
– ident: ref14/cit14
  doi: 10.2147/BTT.S35475
– ident: ref45/cit45
  doi: 10.1101/cshperspect.a001651
– ident: ref40/cit40
  doi: 10.1080/21655979.2021.2012949
– ident: ref26/cit26
  doi: 10.1016/j.autrev.2020.102741
– ident: ref3/cit3
  doi: 10.1111/j.0105-2896.2009.00859.x
– ident: ref6/cit6
  doi: 10.1002/art.40504
– ident: ref20/cit20
  doi: 10.1039/c7fo01748k
– ident: ref37/cit37
  doi: 10.3892/mmr.2017.7706
– ident: ref38/cit38
  doi: 10.1038/s41413-019-0047-x
– ident: ref9/cit9
  doi: 10.1007/s10753-020-01371-1
– ident: ref8/cit8
  doi: 10.1006/cimm.1994.1223
– ident: ref34/cit34
  doi: 10.3390/ijms19051514
– ident: ref2/cit2
  doi: 10.1016/j.intimp.2021.107392
– ident: ref7/cit7
  doi: 10.1038/nprot.2007.173
– ident: ref33/cit33
  doi: 10.1002/jcp.26754
– ident: ref21/cit21
  doi: 10.1186/ar1038
– ident: ref48/cit48
  doi: 10.1038/nbt1328
– ident: ref23/cit23
  doi: 10.1186/s12967-021-03169-7
– ident: ref46/cit46
  doi: 10.1016/j.cmet.2010.12.008
– ident: ref24/cit24
  doi: 10.1186/1471-2474-12-153
– ident: ref53/cit53
  doi: 10.3389/fphar.2021.670707
– ident: ref29/cit29
  doi: 10.4049/jimmunol.1600600
– ident: ref22/cit22
  doi: 10.1038/s41423-019-0201-9
– ident: ref41/cit41
  doi: 10.1155/2020/2138186
– ident: ref1/cit1
  doi: 10.1002/pds.3221
– ident: ref42/cit42
  doi: 10.1155/2021/6617312
– ident: ref49/cit49
  doi: 10.1016/j.toxicon.2019.06.007
– ident: ref43/cit43
  doi: 10.3390/ijms23105813
SSID ssj0001682826
Score 2.2455704
Snippet Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for...
Rheumatoid arthritis (RA) is a chronic joint inflammatory disease associated with the aberrant activation of fibroblast-like synoviocytes (FLSs). Searching for...
SourceID pubmedcentral
proquest
crossref
acs
SourceType Open Access Repository
Aggregation Database
Publisher
StartPage 29868
SummonAdditionalLinks – databaseName: American Chemical Society Journals
  dbid: ACS
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NjtMwELbY5QAX_hHlT0aCAxIG20lj57hbtmKFdlVRkLhFtjPeWoCDSLuo78HT8BA8E-M0YbcIIbhFysSxZiaZbzz2N4Q8HvOae28cg3RsOedgGabNOXPKltJq0BK6JrZzdfxevzw4T5PzewVfihfGtc0nODHPpcMUqih2yEWpECgkGDSZn62nFJg7dN3VZK44E1me9VXJPw2SYpFrt2PRGcDc3h55Lt5Mr_7PTK-RKz2qpHsbN7hOLkC8QS5NhmZuN8m3Q4THXUU9RHoYF8GGZUtnqWWPh40TPKNH4WS4NLFGMY_usjnaSE-DofsY-NLKOkXQSI-n7Mf3_U7waG_2ms4QSn4165biC94sYIXPNaGmU0zHG4sQfck-hg9A5-vYnIbGrRHi3iLvpgdvJ69Y35CBmcRUxkCI0ucqtwgCHcdECEDYsnbeGgWF9ryshfSFKMBjRITE1G_GHBz-Frx2Wma3yW5sItwh1GAi53PQtXZZbn1hODrL2OY-q4UuQYzIE1Rn1X9QbdXVyqWoBh1XvY5H5Olgwurzhp_jL7KPBhtXqP5UGTERmlVboUMhTs5EpkZEbRn_16CJhnv7TgyLjo47Mewpxe_-44zvkcsyHaFI69L8PtldflnBA7LT1quHnUf_BEen93Q
  priority: 102
  providerName: American Chemical Society
Title Imperatorin Inhibits Proliferation, Migration, and Inflammation via Blocking the NF-κB and MAPK Pathways in Rheumatoid Fibroblast-like Synoviocytes
URI http://dx.doi.org/10.1021/acsomega.2c02766
https://search.proquest.com/docview/2709913137
https://pubmed.ncbi.nlm.nih.gov/PMC9434770
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELboXuCC-BXlpzISHJBI6zhp7Rx3y1asUFcVBYlbZDvjrcXWWZF2Ud-Dp-EheCbGbgLbCwdukWInkWei-ebvG0JejVnFrFUmgdC2nDPQCbrNeWKELriWIDnEIbZLcf5FvjsNNDnjrhcmFu0b7Yb-cj30bhVrK6_WZtTViY0W82ngNBOCjXqkh9jwhoseAysTdCJ4l5JEEzZSpqnXcKGG3KATNglTizLE7YEmJtgk0xzapL9A87BM8obdmd0jd1vASI_3H3af3AL_gNyednPaHpIfZ4h8Y7LceXrmV067TUMXYRqPhb1839K5u-gula9wmUVN2Hct0mun6AnatBA0p4gH6fks-fXzJC6cHy8-0AWixO9q11B8wccVbHFf7So6Q0-71oi-N8ml-wp0ufP1tavNDtHrI_J5dvpp-j5pZy0kKpCQJZCmhc1FrhHfGYY-DkCqi8pYrQRMpGVFlXKLZwYWjR0EEn41ZmDwj7fSSJ49Jke-9vCEUIU-ms1BVtJkubYTxVAPxjq3WZXKAtI-eY1nXrb_SlPGNDhPy05MZSumPnnTSaW82lNv_GPty05sJR5_SHooD_W2KblADJxmaSb6RBzI889DA8P24R1UvMi03Sra0__e-Yzc4aFfIgSh2XNytPm2hRek11TbAaL46XIQYwCDqMG_AakR-g4
link.rule.ids 230,315,729,782,786,866,887,2769,27085,27933,27934,53800,53802,56747,56797
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtswDBbW7tBd9j80-9WA7TBgTiTZieVjmzVo0CYI1g7YzZBkqhHWyMWcdMh77Gn2EHumUY69NZcdejNgyTZEyvwokh8JeddnBbNWmQhC2XLCQEfoNieRSXUmtAQpoG5ie5ZOv8pPR4Emp9_WwtRJ-0a7rr9cdL2b17mVVwvTa_PEerPJMHCapSnr7ZC7uF8Zu-Gk10crA3QjRBuURCPWU6YqF3ChusKgGzYIfYtiRO6BKCZYJVNtW6V_UHM7UfKG5Rk9uOU3PyT3G6hJDza3H5E74B-TvWHb4e0J-TlGzFyH2Z2nYz932i0rOgt9fCxsNOMjnbiL9lL5AodZ1KFNvSO9dooeojUMx-0UkSSdjqLfvw7rgZOD2QmdIb78odYVxRd8nsMK55WuoCP00UuNuH0ZXbpvQM_Wvrx2pVkj7n1KvoyOzofHUdOlIVKBviwCzjObpIlGZGgYekcAXGeFsVqlMJCWZQUXFtcaLJpJCPT9qs_A4L_CSiNF_Izs-tLDPqEKvTubgCykiRNtB4qhBvV1YuOCywx4h7xHWeXNLqvyOoAueN6KN2_E2yEfWmnmVxvSjv-MfduKO8flD-ES5aFcVblIET3zmMdph6RbevD3oYGbe_sOir_m6G7E_fzWM9-QvePzyWl-Op6evCD3RKi6CEfZ7CXZXX5fwSuyUxWr17Xm_wGXJA26
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwELfYkICX8V-U8cdI8IBEGsdJm-Rx6xZRjVYRA4m3yHbOq8XqVKTd1O-xT8OH4DNxTpOxvvAAb5FyTiLfOfc73_l3hLwdsJJpLZQH7thyxEB6GDZHnoplymUCCYemie1pPP2WHB07mpzrVl9N0b6Spm_P531rZk1t5WKu_K5OzM8nI8dpFsfMX5Ta3yG3cc0yfiNQb7ZXhhhK8C4xiY7MF6qu5nAm-lxhKDZ0vYtCRO-OLMZ5JlVve6Y_cHO7WPKG98nu_8d3PyB7LeSkBxuRh-QW2Efk7qjr9PaYXI0ROzfpdmPp2M6MNMua5q6fj4aNhXygE3PWXQpbophGW9qce6QXRtBD9Ipu250ioqTTzPv187ARnBzkJzRHnHkp1jXFF3yewQrHVaakGcbqlUT8vvTOzXegp2tbXZhKrRH_PiFfs-Mvo49e263BE47GzIMgSHUURxIRomIYJQEEMi2VliKGYaJZWgZc43yDRncJjsZfDBgo_GfoRCU8fEp2bWXhGaECozwdQVImKoykHgqGljSQkQ7LIEkh6JF3qK-iXW110STSeVB0Ki5aFffI-06jxWJD3vEX2Tedygucfpc2ERaqVV3wGFF0EAZh3CPxli1cP9RxdG_fQRNouLpblT__55GvyZ38KCs-jacn--Qed4cv3I42e0F2lz9W8JLs1OXqVWP8vwHsuxA6
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Imperatorin+Inhibits+Proliferation%2C+Migration%2C+and+Inflammation+via+Blocking+the+NF-%CE%BAB+and+MAPK+Pathways+in+Rheumatoid+Fibroblast-like+Synoviocytes&rft.jtitle=ACS+omega&rft.au=Lin%2C+Wei&rft.au=Chen%2C+Gang&rft.au=Mao%2C+Yuhang&rft.au=Ma%2C+Xuemei&rft.date=2022-08-30&rft.eissn=2470-1343&rft.volume=7&rft.issue=34&rft.spage=29868&rft.epage=29876&rft_id=info:doi/10.1021%2Facsomega.2c02766&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2470-1343&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2470-1343&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2470-1343&client=summon